DCTD Programs
Last Updated: 06/01/2023
2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Schedule of DCTD Presentations
DCTD-supported research will be presented at the ASCO Annual Meeting 
from June 2-6, 2023. The following tables include the oral and
poster sessions containing DCTD staff speakers and co-authors.
Oral Sessions
| Title | Link Date/Time |
|---|---|
| SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL) | Plenary Session
June 4/2:53 pm CDT |
| Innovative Solutions to the Challenges of Cancer Clinical Trials: FDA and NCI perspectives NCI Speakers: James Doroshow, Monica Bertagnolli, Sheila Prindiville |
Education Session
June 5/10:45-12:00 pm CDT |
Poster Sessions
eePublication; OAOral Abstract Session; PPoster Presentation; PDPoster Discussion Session
| Title | Link Abstract # |
|---|---|
| Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials | P1565
|
| Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609) | OA2504
|
| Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab) | P2560
|
| Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas | P3022
|
| Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T) | P3047
|
| Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2 | P3108
|
| Discovery of gene fusions in driver-negative NCI-MATCH screening samples | P3112
|
| A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer | P4044
|
| Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses | PD5512
|
| A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers | PD5517
|
| Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer Presenter: Sarah Shin, MD |
P5564
|
| Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies | P5593
|
| Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance) | OA7500
|
| Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466) | OA9511
|
| Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I) | OA10006
|
| Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B) | OA10007
|
| A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27) | PD11516
|
| PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network study | P11527
|
| ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma | P11531
|
| A phase 2 study of an anti-PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma | P11533
|
| Longitudinal follow-up and outcomes of pediatric and adult patients with SDH-deficient GIST | P11542
|
| A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma | eE21557
|
| Expanding eligibility criteria for renal and liver function in NCI-sponsored immunotherapy clinical trials | eE13610
|
| A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48) | eE16330
|
| Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001 | PTPS4198
|
| A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects. | PTPS4607
|
| A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress | PTPS5110
|
| A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 | PTPS9603
|
| Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors | PTPS10066
|
| Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers | PTPS10071
|
Staff Kiosk Schedule — Booth #6034
| Date | Time | Presenter |
|---|---|---|
| June 3 | 9:00 AM - 11:00 AM 3:00 - 5:00 PM |
Aniruddha Ganguly, PhD Cancer Diagnosis Program |
| June 4 | 9:00 AM - 11:00 AM | Sharad Verma, PhD Developmental Therapeutics Program |
| 11:00 AM - 1:00 PM | Aniruddha Ganguly, PhD Cancer Diagnosis Program |
|
| 1:00 PM - 3:00 PM | Marc S. Ernstoff, MD Developmental Therapeutics Program |
|
| June 5 | 11:00 AM - 1:00 PM | Aniruddha Ganguly, PhD Cancer Diagnosis Program |
| 1:00 PM - 3:00 PM | Lokesh Agrawal, PhD Cancer Diagnosis Program |
|
| 3:00 - 5:00 PM | Aniruddha Ganguly, PhD Cancer Diagnosis Program |